



PCPA Chronic Kidney Disease (CKD) Academy 2025

Advanced Chronic Kidney Disease Management for Clinical Pharmacist Prescribers in Primary Care.

The CKD Academy has been funded by Boehringer Ingelheim who have had no input into the agenda, speaker selection, presentations or collateral.

Priority will be given to PCPA Members who are independent prescribers.

Your application will be judged on your supporting statement.

Places will be limited to 40 pharmacists who are able to undertake the following

- Within your current role, you have access to a significant patient cohort, where you are able to undertake a Baseline Audit from the clinical system of patient data.
- Complete a Quality Improvement Project based on the Baseline Audit by utilising the knowledge, skills, attitudes, and behaviours attained in an area relevant to your practice which can be developed and retained for CQC purposes.
- You will be expected to attend all structured educational sessions and actively engage with expert speakers and faculty

COURSE DATES:

All Academy modules will be held in the evenings, from **20.00-21.30**

The CKD Academy will run from May through to September 2025

Course Induction – 13th May 2025– 20.00-21.00

Module Dates

Module One

- Session 1 – 19th May 2025
- Session 2- 10th June 2025

Module Two

- Session 1 – 18th June 2025
- Session 2 – 25th June 2025

Module Three

- Session 1 – 1st July 2025
- Session 2 – 9th of July 2025

Graduation Celebration Evening – 23rd September 2025

Assignment deadlines

- Baseline Audit – 16th June 2025
- Quality Improvement Project – 2nd September 2025

Course Overview:

This advanced course is designed for clinical pharmacists working in general practice and Primary Care Networks (PCNs). It focuses on providing a comprehensive understanding of Chronic Kidney Disease (CKD) management, equipping pharmacists with the skills and knowledge required to take a lead role in managing patients living with CKD. The course will integrate advanced pharmacological management, holistic care, and the principles of shared decision-making. By the end of the course, pharmacists will be prepared to deliver high-quality, patient-centred care and collaborate effectively with multidisciplinary teams in managing CKD within primary care settings.

Module 1: Advanced Understanding of Chronic Kidney Disease

Module leads

- **Prof. Raj Thakkar**, GP, President and CKD Representative of Primary Care Cardiovascular Society
- **Rani Khatib**, PCPA CKD Academy Lead, National Specialty Advisor for CVD Prevention. Consultant Cardiovascular Pharmacist

Objectives:

- Develop a deeper understanding of CKD pathophysiology and its progression.
- Analyse the risk factors, genetics, and molecular mechanisms contributing to CKD.
- Review national and international guidelines for CKD screening and diagnosis.
- Evaluate the psychosocial, emotional, and lifestyle impacts of CKD on patients and their families.

Module 2: Advanced Pharmacological Interventions and Therapeutic Optimisation in CKD

Module Leads

- **Sara Perkins**, Highly Specialised Renal & Transplant Pharmacist
- **Rani Khatib**, PCPA CKD Academy Lead, National Specialty Advisor for CVD Prevention. Consultant Cardiovascular Pharmacist

Objectives:

- Master advanced pharmacological interventions used in CKD management including the CardioRenalMetabolic interplay.
- Address complex issues related to polypharmacy, renal dosing adjustments, and managing CKD complications.
- Enhance skills in monitoring treatment efficacy and safety, ensuring optimal therapeutic outcomes for patients.
- Emphasize the pharmacist's role in patient education, medication adherence, and supporting patient autonomy.

Module 3: Comprehensive Management of Chronic Kidney Disease in Primary Care

Module Leads

- **Elly Wakeling**, Senior PCN Pharmacist, Population Health Improvement Fellow in CKD Inequalities
- **Rani Khatib**, PCPA CKD Academy Lead, National Specialty Advisor for CVD Prevention. Consultant Cardiovascular Pharmacist

Objectives:

- Deepen understanding of comprehensive, evidence-based CKD management strategies with considerations of the interplay within the CardioRenalMetabolic axis.
- Advance the management of comorbidities, with a focus on integrating these into CKD care.
- Enhance the pharmacist's leadership role in multidisciplinary teams, focusing on holistic and patient-centred care.
- Develop skills in shared decision-making and ensuring patient engagement in their treatment plans.